Aurora Spine (ASG) AI Stock Analysis

• Market Cap: C$21.47M
• Dividend Yield: N/A
• Average Volume (3M): 30.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: 9.71%
• EPS Growth: -118.02%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 78,054,950
• 10 Day Avg. Volume: 38,837
• 30 Day Avg. Volume: 30,190
• PEG Ratio: 0.46
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 78.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.26 ▼(-5.19% Downside)

Aurora Spine's overall stock score is primarily influenced by its mixed financial performance and bearish technical indicators. While recent corporate events show promise with new product launches and strategic growth initiatives, the company's current profitability challenges and negative valuation metrics weigh heavily on the score.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a stable demand for Aurora Spine's products, reflecting its ability to maintain and potentially expand its market presence.

Gross Profit Margin

A strong gross profit margin suggests effective cost management and pricing power, which can support long-term profitability as the company scales.

Moderate Leverage

Moderate leverage indicates a balanced approach to financing, providing the company with the flexibility to invest in growth opportunities without excessive debt burden.

Negative Factors

Profitability Challenges

Persistent profitability challenges could hinder Aurora Spine's ability to reinvest in its business and maintain competitive positioning in the long term.

Negative Return on Equity

A negative ROE indicates that the company is not effectively using its equity base to generate profits, which could impact investor confidence and future capital raising.

Weak Cash Flow Performance

Weak cash flow performance limits the company's ability to fund operations and growth initiatives internally, potentially increasing reliance on external financing.

Aurora Spine Business Overview & Revenue Model

Company Description

Aurora Spine (ASG) is a medical device company focused on developing innovative spinal implants and surgical solutions. The company operates in the orthopedic and spinal surgery sectors, providing a range of products that include interbody fusion devices, spinal fixation systems, and minimally invasive surgical tools. Aurora Spine aims to improve patient outcomes and enhance surgical efficiency through its advanced technology and commitment to research and development.

How the Company Makes Money

Aurora Spine generates revenue primarily through the sale of its spinal implants and surgical instruments to hospitals, surgical centers, and orthopedic surgeons. The company’s revenue model is based on direct sales and distribution agreements with medical facilities, where they supply their products for use in various spinal surgeries. Key revenue streams include the sale of interbody devices, fixation systems, and minimally invasive surgical tools. Additionally, Aurora Spine may benefit from partnerships with healthcare providers and collaboration with other medical technology firms, which can enhance its market reach and product offerings. The company also engages in research and development to innovate and expand its product line, potentially opening new revenue channels through patented technologies and advanced surgical solutions.

Aurora Spine Financial Statement Overview

Summary

Aurora Spine shows a mixed financial performance with revenue growth but persistent profitability challenges. The negative net income and cash flow generation impact its overall financial health. Moderate leverage and negative return on equity highlight areas needing improvement.

Income Statement

Aurora Spine's income statement shows a mixed performance. The company has achieved revenue growth, with a TTM (Trailing-Twelve-Months) revenue increase of 2.33%. However, profitability remains a concern, as indicated by negative net profit and EBIT margins. The gross profit margin is relatively healthy at 59.63%, but the negative net profit margin of -6.04% suggests challenges in controlling costs or achieving operational efficiency.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.89, which is manageable but has increased slightly over time. The return on equity is negative at -23.50%, indicating that the company is not generating profits from its equity base. The equity ratio stands at 34.14%, suggesting a reasonable level of equity financing, but the negative ROE highlights profitability issues.

Cash Flow

Cash flow analysis reveals challenges in generating free cash flow, with a negative growth rate of -22.70% in the TTM period. The operating cash flow to net income ratio is low at 0.20, indicating limited cash generation relative to net income. The free cash flow to net income ratio is 0.29, showing some ability to convert earnings into cash, but overall cash flow performance remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.38M	17.56M	14.52M	14.88M	10.54M	8.65M
Gross Profit	10.96M	10.63M	8.21M	7.81M	4.83M	3.47M
EBITDA	88.66K	179.90K	-446.20K	-469.27K	-1.55M	-573.86K
Net Income	-1.13M	-1.00M	-1.68M	-1.50M	-2.36M	-232.09K
Balance Sheet
Total Assets	11.57M	11.67M	11.99M	10.12M	10.56M	7.16M
Cash, Cash Equivalents and Short-Term Investments	580.98K	775.62K	766.83K	423.40K	3.17M	1.71M
Total Debt	3.63M	3.67M	3.65M	2.97M	2.55M	2.34M
Total Liabilities	7.62M	7.28M	6.69M	5.81M	4.99M	3.87M
Stockholders Equity	3.95M	4.40M	5.30M	4.32M	5.57M	3.28M
Cash Flow
Free Cash Flow	192.57K	266.47K	-1.41M	-2.43M	-2.85M	-245.07K
Operating Cash Flow	719.64K	904.33K	-935.06K	-1.56M	-2.13M	309.57K
Investing Cash Flow	-314.05K	-484.32K	-479.13K	-873.21K	-720.61K	-554.64K
Financing Cash Flow	-343.16K	-361.22K	1.76M	-318.15K	4.31M	1.51M

Aurora Spine Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Neutral. The current price of 0.27 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.29, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.09 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ASG.

Aurora Spine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QIPT	49 Neutral	C$140.76M	-9.69	-9.96%	―	-0.70%	-102.48%
ASG	47 Neutral	C$21.47M	―	-31.12%	―	9.71%	-118.02%
TLT	47 Neutral	C$39.84M	-8.86	-269.41%	―	1.46%	6.91%
PINK	46 Neutral	C$29.10M	-0.90	-181.70%	―	209.29%	35.38%
VPT	44 Neutral	C$14.25M	―	―	―	28.59%	23.46%
PMED	35 Underperform	C$12.64M	―	―	―	―	24.18%

Aurora Spine Corporate Events

Aurora Spine Reports Record Q3 2025 Results Amid Product Launches

Aurora Spine Corporation announced record financial results for the third quarter of 2025, marking a significant period of transition with the launch of two new product platforms, DEXA-L and Hydra ARO. Despite a slight decrease in total revenues compared to the previous year, the company achieved positive EBITDAC for the second consecutive quarter, reflecting efficient operations and market expansion. The introduction of new products is expected to act as growth catalysts, with initial sales already achieved, reinforcing Aurora Spine’s commitment to innovation and diversification in the spine and pain markets.

Aurora Spine to Showcase Innovations at NASS 2025

Aurora Spine Corporation announced its participation in the 2025 North American Spine Society Annual Meeting, where it will showcase its latest innovations at Booth #1622. The company will feature its newly launched Hydra Facet Fusion System and the DEXA-L device, part of its DEXA Technology Platform, which offers personalized spinal care through patient-matched implants. These advancements are expected to transform spinal surgery and enhance Aurora Spine’s industry positioning.

Aurora Spine Unveils Aurora Biologics to Enhance Spinal Fusion Success

Aurora Spine has launched Aurora Biologics, a new division aimed at enhancing spinal fusion success through innovative biologic solutions. This launch integrates seamlessly with Aurora’s existing spine ecosystem, offering a comprehensive platform that optimizes patient outcomes and surgical efficiency. The introduction of Aurora Biologics is expected to drive significant growth, with anticipated revenue increases and improved profit margins, positioning Aurora Spine as a leader in biologic performance in spine care.

Aurora Spine Proposes Extension of Warrant Expiry Date

Aurora Spine Corporation has announced a proposed extension of the expiry date for 6,445,939 common share purchase warrants to October 15, 2026, pending approval from the TSX Venture Exchange. This move is part of the company’s strategic efforts to enhance its financial flexibility and potentially strengthen its market position in the spine and interventional pain management industry.

Aurora Spine Launches Innovative Bone Density-Matched Lumbar Fusion Device

Aurora Spine has launched the DEXA-L™ Anterior Lumbar Interbody Fusion Device, a groundbreaking product in its DEXA™ Technology Platform. This device is the first of its kind, offering a bone density-matched implant for anterior lumbar interbody fusion procedures. It allows surgeons to tailor implants to match the bone density and quality of each patient, expanding treatment options for those with varying bone conditions, including osteopenia and osteoporosis. This advancement is expected to significantly impact the spinal surgery field by providing more personalized and effective treatment options.